Nonclinical in vivo assessment of
QT interval in cardiovascular safety pharmacology studies has limited predictive value as well, often necessitating a «Thorough QT» clinical study later in development.
The cost of these large
QT interval clinical trials is not trivial either, while the data collected about
QT interval is again only a small piece of the story when investigating proarrhythmic risk of a drug.
Not exact matches
161/6: 30 Investigating the effects of coding variants on
QT and JT
intervals utilizing data from 95,626 individuals.